Published in Nucleic Acid Ther on July 25, 2011
pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano (2013) 1.13
Molecular factors in dendritic cell responses to adsorbed glycoconjugates. Biomaterials (2014) 0.77
Iron Oxide Nanoparticles Coated with a Phosphorothioate Oligonucleotide and a Cationic Peptide: Exploring Four Different Ways of Surface Functionalization. Nanomaterials (Basel) (2015) 0.75
Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses. PLoS One (2017) 0.75
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 9.09
Primary brain tumours in adults. Lancet (2003) 3.05
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol (2009) 2.65
TrxG and PcG proteins but not methylated histones remain associated with DNA through replication. Cell (2012) 2.45
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol (2003) 2.43
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Differential labeling of myosin V heads with quantum dots allows direct visualization of hand-over-hand processivity. Biophys J (2005) 2.31
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res (2012) 1.67
PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med (2003) 1.60
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol (2006) 1.52
Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol (2007) 1.48
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 1.43
Endochondral growth in growth plates of three species at two anatomical locations modulated by mechanical compression and tension. J Orthop Res (2006) 1.39
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother (2009) 1.30
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol (2010) 1.30
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol (2006) 1.23
Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer (2005) 1.18
Distribution and structure-function relationship of myosin heavy chain isoforms in the adult mouse heart. J Biol Chem (2007) 1.15
Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol (2012) 1.12
Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res (2010) 1.12
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol (2005) 0.97
Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol (2012) 0.96
Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother (2008) 0.96
Expression of TLR9 within human glioblastoma. J Neurooncol (2008) 0.95
Alteration of connexin expression is an early signal for chronic kidney disease. Am J Physiol Renal Physiol (2011) 0.92
Steroid requirements during radiotherapy for malignant gliomas. J Neurooncol (2010) 0.91
Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res (2011) 0.88
Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. J Neurooncol (2015) 0.88
Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv Exp Med Biol (2012) 0.88
CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci Lett (2002) 0.85
Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases. J Neurooncol (2005) 0.82
[Brain metastases epidemiology and biology]. Bull Cancer (2013) 0.79
Initial experience using awake surgery for glioma: oncological, functional, and employment outcomes in a consecutive series of 25 cases. Neurosurgery (2015) 0.79
Neurological disorders in essential thrombocythemia. Haematologica (2011) 0.78
Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? Future Oncol (2014) 0.78
[Management of brain metastases for lung cancer patients]. Bull Cancer (2013) 0.76
Cytokine content in lymphoid and white adipose tissues after repeated CpG oligodeoxynucleotide administration in trained rats. Vaccine (2009) 0.75
Superficial siderosis of the central nervous system: a rare cause of dementia with therapeutic consequences. Age Ageing (2012) 0.75
[Chemotherapy and targeted therapies in the management of brain metastases]. Rev Prat (2014) 0.75
[Clinical symptoms and symptomatic management of brain metastases]. Bull Cancer (2011) 0.75